['t2 diabetes and fatty liver disease (non-alcoholic origin)']
['placebo', 'omega-3 carboxylic acids', 'dapagliflozin', 'placebo']

        Inclusion Criteria: Provision of informed consent prior to any study specific procedures;
        Men or women ≥40 years and ≤75 years with suitable veins for cannulation or repeated
        venepuncture; Have liver fat content as assessed by MRI >5.5%; Diagnosis of Type 2 diabetes
        since at least 6 months in accordance with WHO criteria.

        Exclusion Criteria: Any condition when MRI is contraindicated such as, but not limited to,
        having a pacemaker or claustrophobia; Diagnosis or signs of Type 1 diabetes (e.g. history
        of positive islet antibodies); Creatinine clearance <60 mL/min at screening
        (Cockcroft-Gault formula).
      